Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
about
Parkinson's disease and primate research: past, present, and futureNonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeysEffect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's diseaseThe neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.Effect of exercise on dopamine neuron survival in prenatally stressed rats.Large animal models are critical for rationally advancing regenerative therapiesNatural toxins implicated in the development of Parkinson's disease.Evaluation of hydrodynamic limb vein injections in nonhuman primates.Systemic administration of 6-OHDA to rhesus monkeys upregulates HLA-DR expression in brain microvasculatureResponse of aged parkinsonian monkeys to in vivo gene transfer of GDNFThe role of pramipexole in a severe Parkinson's disease model in miceNonhuman primate models of Parkinson's disease.Preclinical assessment of stem cell therapies for neurological diseases.JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-hydroxydopamine Model of Parkinson's Disease.The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.NMR Metabolomics Analysis of Parkinson's DiseaseMitochondrial dysfunction and oxidative stress promote apoptotic cell death in the striatum via cytochrome c/caspase-3 signaling cascade following chronic rotenone intoxication in ratsExposure to Early Life Stress Results in Epigenetic Changes in Neurotrophic Factor Gene Expression in a Parkinsonian Rat Model.Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.Parkinson's disease: genetic versus toxin-induced rodent models.Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy.Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagyAnimal models of human amyloidoses: are transgenic mice worth the time and trouble?Pedunculopontine stimulation from primate to patient.Parkinson's disease mouse models in translational research.Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's DiseaseRole of the pedunculopontine nucleus in controlling gait and sleep in normal and parkinsonian monkeys.Manganese inhalation as a Parkinson disease model.Physical Training Regulates Mitochondrial Parameters and Neuroinflammatory Mechanisms in an Experimental Model of Parkinson's Disease.Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.Cell transplantation and gene therapy in Parkinson's disease.Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.Age-related decline in motor behavior and striatal dopamine transporter in cynomolgus monkeys.Exercise improves motor deficits and alters striatal GFAP expression in a 6-OHDA-induced rat model of Parkinson's disease.MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes.Animal care and use issues in movement disorder research.
P2860
Q24655590-77031EA5-BB55-4320-A503-C0245CBA7FA6Q31059759-D361CE33-C076-4FA0-9BE0-A2F79E316D6FQ33597885-F5E1A408-5D23-4C21-A2DA-73FAF34CE7EBQ33778472-583AC2B9-AD56-4AD1-9C2C-EE86E55285FBQ33824302-4B7009DD-6996-443D-AA75-03F9F816B911Q33999256-B809BAAB-20F4-4B02-8D16-889DF38B1F11Q34029794-D64F735B-FBBF-4321-9742-E430F02AD95DQ34123298-8EFD745D-55E1-4B61-9ED0-096E220BB423Q34237258-315367F2-9598-4E5C-8B5F-B996CDCBD74AQ34339833-4F4D8A51-F529-4A9C-9E10-F911E6BB959EQ34409425-1C266EC2-CB93-4A4E-A26D-3127DF53A89CQ34665820-F589AD99-153C-4D87-8BAA-F6DB5918B833Q34786764-120FCA45-8247-4B77-992A-177AD05E4D34Q35031088-9A4BE5E1-1411-4822-8009-74A899FF6CBAQ35196195-B3F570C4-B171-4B15-997E-0BD7A512EBCFQ35734379-059A1C48-83E4-48CA-88B8-3C04644DC7DBQ36197290-27F9E752-FA16-4FB5-8134-A0B2AC6606F1Q36528892-FD462C77-6C9C-4325-9738-75729A18482FQ36994301-4361DC17-1ACB-4DDE-8BE8-F40C0D1C9499Q37076726-882B8861-58F5-48E4-A00A-8D804299B8DCQ37086124-6CE2250D-0F50-45A9-9797-D03A5C502706Q37203372-E94EA6AE-BFC4-4724-B69A-CDDE146BE2C2Q37256315-41F567FF-F315-4C12-8624-B6A68DFE31F0Q37535690-665B68EC-0BCF-439A-B001-397FC3D4401EQ37560167-CA3CA8D6-FC56-459D-B944-99E7FCF68A5FQ37859316-23D26691-714E-4BAC-ADB6-4192AAF30DF1Q37874160-15046844-CDCB-4B84-9E88-81F24033AD78Q38463391-E84E5D58-67AE-4E6B-ADDE-D7D08B8A7EFDQ39085391-E5D179FB-72A0-41B2-9C7E-F283E547A133Q41488197-E932E2B7-7E33-4126-BF7D-572E48B9038DQ42271780-4921E384-0CB9-49DD-B371-25B0525B8225Q42512645-F1BD1A09-4254-48D8-9EA6-ACDC44BCFF9EQ44266420-A27F0D24-7EC1-40AE-A67E-F6BB9762C107Q44297524-BED78502-9579-47DF-A033-F84AC1C2E404Q45859700-FE48CE1A-B6C7-4FD9-8FB1-41F12D78E888Q48108548-A6846985-C4C9-4319-9131-223960D53426Q48663776-8A4DE497-FD2F-4723-A9F7-C9FEC435DC40Q48720466-CDD5C6C9-24D0-4FF8-8ADD-A194FF413384Q49197319-BF0B4119-6649-48F6-BFF7-922135D70520Q50890705-9DD441F3-65BD-4513-A919-071234312820
P2860
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
@ast
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
@en
type
label
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
@ast
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
@en
prefLabel
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
@ast
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
@en
P1476
Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
@en
P304
P356
10.1016/J.JNEUMETH.2004.08.004
P577
2004-10-01T00:00:00Z